reported that it recorded total revenues of $997,515 and a net loss of $3,740,494 or ($0.03) per share for the three month period ended June 30, 2008.

This is pretty much as I would expect, cash burn rate is increasing and will likely go up even more in Q3, we may not see much revenue increase, peerhaps a little in Q4 although 2009 looks like a stellar year.

S. Wayne Kay, Chief
Executive Officer. "Our announced strategic partnership with Roche Diagnostics, the largest in vitro diagnostics company in the world, to commercialize our cardiovascular tests and new RAMP® 200 Reader solidifies our commercialization strategy. Coupled with our partnerships with 3M and Shionogi, we believe we are poised for rapid market expansion of our RAMP® platform. "

More should be in the Sedar filings which we may be able to read tommorrow

~~ Dimar